Accreditation/Credit Designation

Physicians’ Education Resource®, LLC, is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Physicians’ Education Resource®, LLC, designates this enduring material for a maximum of 2.0 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Physicians’ Education Resource®, LLC, is approved by the California Board of Registered Nursing, Provider #16669, for 2.0 Contact Hours.

Acknowledgment of Commercial Support

This activity is supported by educational grants from AstraZeneca and Daiichi Sankyo, Inc.

Community Practice Connections™: Optimal Patient Management for HER2+ Breast Cancer: Navigating ILD and Other Treatment-Related Side Effects

Release Date: August 31, 2020
Expiration Date: August 31, 2021

Activity Overview

This online education activity is designed to provide expert commentary regarding recent clinical data on the efficacy and safety of antibody-drug conjugates (ADCs) and other new agents for HER2-positive metastatic breast cancer. Management of significant and potentially serious adverse events associated with these agents, including interstitial lung disease (ILD), and how to integrate these agents safely into current treatment algorithms are also discussed. This activity is presented in a multimedia format that includes a series of video interviews with an expert thought leader integrated with text-based elements.

Acknowledgment of Commercial Support

This activity is supported by educational grants from AstraZeneca and Daiichi Sankyo, Inc.

Instructions for This Activity and Receiving Credit

  1. Complete the activity (including pre- and post-activity assessments).
  2. Answer the evaluation questions.
  3. Request credit using the drop-down menu.

You may immediately download your certificate.

Target Audience

This activity is directed toward medical, surgical, and radiation oncologists who treat or manage patients with breast cancer. Fellows, nurses, nurse practitioners, physician assistants, researchers, pathologists, pharmacists, and other healthcare professionals interested in the treatment or management of these tumors are also invited to participate.

Learning Objectives

Upon successful completion of this educational activity, you should be better prepared to:

  • Examine the mechanistic rationale supporting the role of HER2-directed ADCs in breast cancer
  • Discuss recent safety and efficacy data pertaining to the application of HER2-directed ADC therapies in metastatic breast cancer
  • Identify strategies to effectively manage ILD and other treatment-related adverse events associated with HER2-directed therapies in the treatment of patients with metastatic breast cancer
  • Review effective counseling strategies for patients with breast cancer who are being treated with novel HER2-directed therapies

Faculty, Staff, and Planners’ Disclosures

In accordance with ACCME Guidelines, PER® has identified and resolved all COI for faculty, staff, and planners prior to the start of this activity by using a multistep process.


Ian E. Krop, MD, PhD
Ian E. Krop, MD, PhD
Associate Chief, Division of Breast Oncology
Dana-Farber Cancer Institute
Associate Professor of Medicine
Harvard Medical School
Boston, MA

Disclosures: Grant/Research Support: Genentech; Pfizer; Daiichi-Sankyo; Taiho Oncology; Seattle Genetics. Consultant: Genentech; Daiichi-Sankyo; Macrogenics, Context Therapeutics; Taiho Oncology; Merck; Novartis; BMS; Seattle Genetics, Ionis Pharmaceuticals

The staff of Physicians' Education Resource®, LLC (PER®) have no relevant financial relationships with commercial interests to disclose.

Off-Label Disclosure and Disclaimer

This activity may or may not discuss investigational, unapproved, or off-label use of drugs. Learners are advised to consult prescribing information for any products discussed. The information provided in this accredited activity is for continuing education purposes only and is not meant to substitute for the independent clinical judgment of a healthcare professional relative to diagnostic, treatment, or management options for a specific patient’s medical condition. The opinions expressed in the content are solely those of the individual faculty members and do not reflect those of PER® or any company that provided commercial support for this activity.

Login or Register to Start Activity

Please use the form below to Register or Log In to begin Activity.

*Required Fields
Calendar of Events
Filter By